Romidepsin solid forms and uses thereof

Patent metadata

Field	Value
Publication number	US-9624271-B2
Application number	US-201514937804-A
Country	US
Kind code	B2
Filing date	Nov 10, 2015
Priority date	Jul 12, 2010
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.

First claim

The invention claimed is:

1. Amorphous romidepsin, wherein the amorphous romidepsin is obtained from an isopropanol-trifluoroethanol/methanol mixture.

2. The amorphous romidepsin of claim 1 , wherein the amorphous romidepsin exhibits a glass transition temperature of approximately 91° C.

3. The amorphous romidepsin of claim 1 , wherein a thermogravimetric analysis (TGA) thermogram exhibits a weight loss of 3.5%.

4. A composition comprising the amorphous romidepsin of claim 1 and an excipient, wherein the excipient is selected from the group consisting of a cellulose derivative, gum, dextran, vinyllactam, cyclodextrin, gelatin, sugar alcohol, polyhydric alcohol, polyethylene glycol (PEG) polymer, polyethylene oxide, polyethylene derivative, polyvinyl alcohol, propylene glycol derivative, sodium lauryl sulfate (SLS), polysorbate, and methacrylic acid co-polymer.

5. The composition of claim 4 , wherein the excipient is a cellulose derivative.

6. The composition of claim 5 , wherein the cellulose derivative is hydroxypropylmethyl cellulose (HPMC) polymer, hydroxypropyl cellulose, ethyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, or sodium carboxymethyl cellulose.

7. The composition of claim 6 , wherein the cellulose derivative is HPMC polymer.

8. The composition of claim 7 , wherein the molecular weight of the HPMC polymer is in the range between about 10,000 and about 1,500,000 D.

9. The composition of claim 7 , wherein the HPMC has a viscosity in water that is in a range between about 100 and about 100,000 cP measured at a concentration of 2% (w/w).

10. The composition of claim 7 , wherein the HPMC polymer exhibits about 15% to about 35% methoxy substitution.

11. The composition of claim 7 , wherein the HPMC polymer exhibits about 3% to about 15% hydroxypropoxy substitution.

12. The composition of claim 7 , wherein the HPMC polymer is hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose acetate phthalate (HPMC-AP), hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose acetate trimellitate (HPMC-AT) or hydroxypropylmethyl cellulose phthalate (HPMC-P).

13. The composition of claim 4 , wherein the excipient is a PEG polymer.

14. The composition of claim 13 , wherein the PEG polymer has a molecular weight of about 5,000 to about 20,000 D.

15. The composition of claim 4 , wherein the excipient is polysorbate.

16. The composition of claim 15 , wherein the polysorbate is polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, or polysorbate 80.

Assignees

• Celgene Corp

Inventors

• Hanko Jason
• Engers David Alan
• Hagen Eric
• Smolenskaya Valeriya
• Stults Jeffrey Scott

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title